Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-408-5 | CAS number: 103429-90-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral LD50 in rats for both sexes combined = 4600 mg/kg.
Dermal LD50 in rats > 2000 mg/kg
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1983-07-07 to 1983-07-27
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: No GLP compliance claim, no International Test Guidelines quoted (but all parameters are closely comparable to a guideline method) and the purity of the test substance is not reported.
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- A preliminary study was conducted using single oral doses of 1.0 and 5.0 g/kg in two male and two female rats at each dose level. The preliminary rats were observed for clinical signs and mortality over a period of five days.
On the basis of the results of the preliminary study, the main study was conducted at dose levels 0 (control), 1.6, 2.5, 4.0, and 5.0 g/kg bodyweight. Five rats of each sex were used at each dose level. Following a single oral dose, the rats were observed for clinical signs and mortality over a period of fourteen days. Bodyweights were recorded on days 1, 8, and 15. All surviving animals were sacrificed at day 15, and a macroscopic post mortem examination was conducted on all rats at death. - GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hacking and Churchill Limited, Huntingdon, Cambridgeshire, England
- Age at study initiation: 4 - 6 weeks
- Weight at study initiation: 90 - 131 g
- Fasting period before study: Overnight
- Housing: Metal cages with wire mesh floors
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: Minimun period of 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 25-29
- Mean Relative Humidity (%): 57
- Air changes (per hr): approx 15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: Not applicable - test material was dosed as supplied.
MAXIMUM DOSE VOLUME APPLIED: 5.2 mL/Kg (specific gravity = 0.96 g/mL) - Doses:
- 0 (control=distilled water), 1.6, 2.5, 4.0, and 5.0 g/kg in main study
1.0 and 5.0 g/kg in preliminary study - No. of animals per sex per dose:
- 5/sex/group in the main study
2/sex/group in preliminary study - Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days (5 days for preliminary study)
- Frequency of observations and weighing: observations were taken regularly on day 1, and at least twice daily on subsequent days. Bodyweights were recorded on days 1, 8, and 15, and at death.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight - Statistics:
- The acute median lethal oral dose (LD50) to male and female rats was calculated using the method of:
Finney (1971) Probit Analysis (3rd Edition) Cambridge University Press. - Preliminary study:
- The results of the preliminary study indicated that the acute median lethal oral dose (LD50) to rats of 3-methyl-3-methoxybutyl acetate was between 1.0 and 5.0 g/kg bodyweight.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 4 600 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 4 200 - 5 000
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 4 700 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 4 100 - 5 400
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 4 500 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 3 900 - 5 100
- Mortality:
- Mortailties occurred amongst rats treated at 4.0 and 5.0 g/kg bodyweight within 22 to 71 hours of dosing.
3 males and 3 females dosed at 5.0 g/kg were found dead at the first observation of day 2; a further male from this group was found dead at the first observation on day 3 and a further female at the second observation of day 3. One female rat dosed at 4.0 g/kg was found dead at the first observation of day 4. - Clinical signs:
- Abnormal body carriage (hunched posture), lethargy, decreased respiratory rate, increased salivation and ataxia was observed amongst treated rats.
Ptosis was seen in all rats treated at 2.5 g/kg and above.
Comatose-like condition was seen amongst rats treated at 4.0 and 5.0 g/kg.
Increased lacrimation was seen in four rats at 4.0 g/kg.
Pilo-erection only was observed in control animals. - Body weight:
- Poor weight gain was recorded in the occasional male rat at 2.5 g/kg and above and the occasional treated female rat on Day 8. Bodyweight gains were normal on Day 15.
- Gross pathology:
- Terminal autospy findings were normal.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute median lethal oral dose and their 95% confidence limits to rats of MMB-Ac were estimated to be:
Males and females combined: 4.6 (4.2 to 5.0) g/kg bodyweight
Males Only: 4.7 (4.1 to 5.4) g/kg bodyweight
Females Only: 4.5 (3.9 to 5.1) g/kg bodyweight
Reference
Dose (g/kg) | Mortality ratio(No.ofdeaths)/(No.dosed) | Time of death after dosing |
||
Males | Females | Combined | ||
1.0 | 0/2 | 0/2 | 0/4 | - |
5.0 | 2/2 | 2/2 | 4/4 | <22 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 4 600 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1992-07-02 to 1992-07-16
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Although a good quality report and conducted to GLP and documented test parameters are based on specific national guidelines, the purity of test substance is not reported and actual guidelines refs not quoted in test report.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Principles of method if other than guideline:
- No official test guidelines were cited, although on review of the test report, the methodology used was broadly consistent with OECD test guideline 402.
- GLP compliance:
- yes
- Remarks:
- The test report includes a statement of GLP compliance signed by the Study Director, and a statement of Quality Assurance, however no certificate of GLP compliance issued by an independant body (such as an official GLP monitoring authority) was included.
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: males: 9-10 weeks; females: 11-12 weeks
- Weight at study initiation: males: 259-287 g; females:225-256 g
- Fasting period before study:
- Housing: housed by sex in polypropylene cages with mesh floors suspended over absorbent paper lined trays with maximum 5 animals per cages
- Diet: ad libitum
- Water: ad libitum)
- Acclimation period: 9 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-22
- Mean Relative Humidity (%): 48
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: back
- Area % - 10
- Type of wrap if used: gauze dressing (5x5 cm)
REMOVAL OF TEST SUBSTANCE
- Washing: skin was wiped with a water dampened tissue
- Time after start of exposure: 24 h
- Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: frequently on the day of dosing and once daily for 14 days following dosing; Animals were weighted immediatey prior to doing, 7 days after dosing and at sacrifice at the end of the 14 day observation period
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: red nasal discharge 4 hours after dosing; low body weight gains for females - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: No mortalities and no abnormal clinical signs were observed in any of the 5 males and 5 females dosed.
- Mortality:
- No moralities
- Clinical signs:
- Red nasal discharge 4 hours after dosing
- Body weight:
- Low body weight gains for females
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The Median Dermal Lethal Dose (LD50) of MMB-Ac in rats is greater than 2000 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Acute oral toxicity
An acute oral toxicity study was conducted in rats. No formal official test guideline was available at the time of the test, and no formal claim of GLP compliance was made, although the study report contained a quality assurance statement.
A preliminary test was conducted at dose levels 1000 and 5000 mg/kg; two animals per sex per dose level were administered a single oral dose, then observed for clinical signs for five days. On the basis of this preliminary study, dose levels for the main study were determined.
In the main study five rats per sex per dose level were administered a single oral dose by gavage. Dose levels in the main study were 0 (control level), 1600, 2500, 4000, and 5000 mg/kg bodyweight. Following test substance administration, the animals were observed for clinical signs and mortality for 14 days. Surviving animals were sacrificed on day 14 of the observation period and a macroscopic post mortem examination of each animal was conducted.
The acute median lethal oral dose and their 95% confidence limits to rats of the test substance were estimated to be:
Males and females combined: 4600 (4200 to 5000) mg/kg bodyweight..
Males Only: 4700 (4100 to 5400) mg/kg bodyweight.
Females Only: 4500 (3900 to 5100) mg/kg bodyweight.
Justification for classification or non-classification
The determined acute oral toxicity gave an LD50 value greater than 2000 mg/kg for both sexes. On this basis the test substance does not require classification as acutely toxic according to either the Dangerous Substances Directive (Directive 67/548/EEC) or the CLP Regulation (EC Regulation 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.